Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Genmab A/S Toldbodgade 33 1253 Copenhagen K Denmark Tel + 45 7020 2728 Fax + 45 7020 2729 CVR no. 2102 3884 Contact: Helle Husted Director, Investor Relations T: +45 33 44 77 30 M: +45 25 27 47 13 E: [email protected] GENMAB INITIATES HUMAX-CD20 CLL PIVOTAL STUDY Summary: Genmab has initiated a Phase III pivotal study in HuMax-CD20 to treat CLL patients failing available therapies. Copenhagen, Denmark; May 23, 2006 – Genmab A/S (CSE: GEN) announced today it has initiated a Phase III pivotal study with HuMax-CD20™ (ofatumumab) to treat patients with refractory B-cell Chronic Lymphocytic Leukemia (CLL). HuMax-CD20 received a Fast Track designation from the FDA in December 2004 for this indication. The study will include approximately 100 CLL patients who have failed treatment with fludarabine and alemtuzumab or who have failed fludarabine and are intolerant to or ineligible for alemtuzumab. “We are excited to begin the pivotal study for HuMax-CD20 in Chronic Lymphocytic Leukemia,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. “We hope HuMax-CD20 will become a new alternative to CLL patients who do not respond to currently available therapies.” About the trial Patients in the single arm trial will receive 8 weekly infusions of HuMax-CD20, followed by 4 monthly infusions of HuMax-CD20. Patients will receive 300 mg of HuMax-CD20 at the first infusion and 2,000 mg of HuMax-CD20 at each subsequent infusion. Disease status will be assessed every 4 weeks until week 28 and then every 3 months until disease progression or month 24. The objective of the study is to evaluate the efficacy and safety of HuMax-CD20 and the primary endpoint is objective response over a 24 weeks period from start of treatment. The responses will be assessed by an Independent Endpoints Review Committee according to the National Cancer Institute Working Group guidelines. Genmab A/S 1/3 Stock Exchange Release no. 23/2006 GENMAB INITIATES HUMAX-CD20 CLL PIVOTAL STUDY About CLL CLL is the most common leukemia in adults in the US and most of Western Europe. The incidence is 8,100 to 12,500 new cases in the US per year and 85-95% of the cases are of B-cell origin. CLL is a subgroup of non-Hodgkin’s lymphoma (NHL) and together with small lymphocytic lymphoma (SLL) corresponds to around 20% of all NHL cases. Conference Call Genmab will hold a conference call to discuss the news tomorrow, Wednesday, May 24, 2006 at: 3.30 pm CEST 2.30 pm BST 9.30 am EDT The dial in numbers are as follows: +1 800 406 5356 (in the US) and ask for the Genmab conference call +1 913 981 5572 (outside the US) and ask for the Genmab conference call The conference call will be held in English. International Non-proprietary Name (INN) Ofatumumab has reached the status of recommended INN, which is the international nonproprietary name (generic name) for HuMax-CD20, as adopted by WHO. About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com. This press release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to Genmab A/S 2/3 Stock Exchange Release no. 23/2006 GENMAB INITIATES HUMAX-CD20 CLL PIVOTAL STUDY manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD4®; HuMax-EGFr™; HuMax-Inflam™; HuMax-CD20™; HuMax-TAC™; HuMax-HepC™ and HuMax-CD38™ are all trademarks of Genmab A/S. UltiMAb® is a trademark of Medarex, Inc. ### Genmab A/S 3/3 Stock Exchange Release no. 23/2006